Publishing in the Journal of Clinical Oncology, researchers at the Mayo Clinic sought to better understand why it is that people diagnosed with chronic lymphocytic leukemia (CLL) are sometimes diagnosed shortly thereafter with mesothelioma or merckel cell carcinoma, at a rate higher than found in the general public.
An association between malignant melanoma and non-Hodgkin’s lymphomas (including CLL) has long been known to exist; in fact malignant melanoma occurs 2.3 to 3.1 times more often in patients with NHLs. However, this is among the first studies to look at whether the lymphomas influence outcomes in melanomas.
"... This is the first study to really solidify that the aggressive forms of skin cancer — namely melanoma and Merkel cell carcinoma — behave worse in people with lymphoma,” Brewer said. “Not only do these patients have worse overall survival, but their chances of dying from metastatic melanoma or metastatic Merkel cell carcinoma is also significantly increased. It would be prudent to educate our patients with lymphoma of this phenomenon and have them be seen by a dermatologist for regular skin examinations.”
Source: HemOncToday
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...